Trial Profile
The retrospective analysis of hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 06 Dec 2018 New trial record